A First-line Immunotherapy for Certain Colon Cancers
The FDA approved the use of an immune checkpoint inhibitor as a first-line treatment for patients with colorectal cancers...
Progress Against Cancer
The FDA approved the use of an immune checkpoint inhibitor as a first-line treatment for patients with colorectal cancers...
The FDA approved the use of an immune checkpoint inhibitor to treat certain patients with cutaneous squamous cell carcinoma. ...
Editor’s Note: On April 30, 2026, the FDA withdrew the accelerated approval of selinexor for this indication. The FDA...
The FDA approved the use of a companion diagnostic to identify patients with tumors that have large numbers of...
The FDA approved an analog of a marine compound to treat certain patients with small cell lung cancer. The...
The FDA approved the use of an immune checkpoint inhibitor to treat certain patients with a common form of...
The FDA approved a combination of an immunotherapy and a therapeutic that can stop tumors from growing blood vessels...
The FDA has expanded the use of the PARP-targeted therapeutic olaparib to include the treatment of certain patients with...
The FDA has approved a new molecularly targeted therapeutic for treating certain patients who have advanced gastrointestinal stromal tumors. The...
The FDA has expanded the use of a molecularly targeted therapeutic to include the treatment of certain patients with...